Sentences with phrase «cells from patients with»

By reprogramming human skin cells and other cells from patients with neurologic and psychiatric diseases into induced pluripotent stem cells (iPSCs) and induced neurons (iN), his work seeks to decipher the progression and mechanisms that lead to brain cell dysfunction.

Even cooler, scientists are now able to «reprogram» human skin cells from patients with neurological disorders and grow them into brain cells [source: Kavli Foundation].

246/3: 00 Quantitative cell image - based high content screening identifies brain permeable small molecules that rescue peroxisome assembly defects in cells from patients with Zellweger spectrum disorder.

They reprogrammed adult skin cells from patients with NOTCH1 mutations into a kind of stem cell called induced pluripotent stem cells (iPSCs).

Daley and other scientists are using iPS technology to reprogram cells from patients with diseases such as Lou Gehrig's disease (amyotrophic lateral sclerosis), Huntington's disease, and diabetes.

Morrow reviewed a final study from his own laboratory, which examines induced pluripotent stem cells from patients with CS.

Paul Insel, MD, professor of pharmacology and medicine, will investigate the expression of the GPCR family of receptors on the surface of cells from patients with chronic lymphocytic leukemia (CLL).

His laboratory has developed a number of techniques to study the molecular profiles of circulating and airway immune cells from patients with asthma and other diseases, using fewer cells than was possible previously.

CD4 + T - cells from patients with HIV - 1 were transduced with a lentiviral vector containing an antisense sequence against the HIV - 1 envelope.

Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

«Metabolic rescue in pluripotent cells from patients with mtDNA disease» by Shoukhrat Mitalipov et al. published in Nature on Wednesday 15th July.

«This step opens up an opportunity to take cells from patients with genetic blood disorders, use gene editing to correct their genetic defect, and make functional blood cells,» said Ryohichi Sugimura, a doctor at Boston Children's Hospital and lead author of one of the studies.

Working at the University of California, Davis, the researchers created a new cellular model for studying Down syndrome by taking skin cells from patients with Down syndrome and inducing them into a pluripotent state.

Transgene - free disease - specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes.

Steven A. Rosenberg and colleagues show that bulk T cells transduced with T cell receptor genes are used to treat patients with melanoma, bypassing the need to expand tumor - specific T cells from patients with cancer.

The team has already created or obtained iPS cells from patients with varying lengths of CAG expansion and from their unaffected family members.

«Studies are underway to interrogate the genomic signature of circulating pancreas cells from patients with precancerous cystic lesions,» says Rhim.

Researchers at Johns Hopkins have successfully corrected a genetic error in stem cells from patients with sickle cell disease, and then used those cells to grow mature red blood cells, they report.

In the future, we would like to study skin cells from patients with disorders of motor neurons.

In a new study, researchers at Boston Children's Hospital used stem cell technology to create cerebellar cells known as Purkinje cells from patients with tuberous sclerosis complex (TSC), a genetic syndrome that often includes ASD - like features.

«We see this mild increase in Aβ42 in cells from patients with Alzheimer's disease, which seems to be enough to trigger disease processes,» said Young - Pearse, a Harvard Stem Cell Institute - affiliated faculty member at Brigham and Women's Hospital.

In a new study published in Molecular Psychiatry the researchers describe how cells from patients with the severe developmental disease lissencephaly differ from healthy cells.

In a collaborative effort between the Gladstone laboratories of Benoit Bruneau, PhD, Katherine Pollard, PhD, and Dr. Srivastava, the scientists used stem cell technology to make large amounts of endothelial cells from patients with CAVD, comparing them to healthy cells and mapping their genetic and epigenetic changes as they developed into valve cells.

In the present study, her team took skin cells from patients with lissencephaly and turned them into iPS cells, which they then cultivated under special conditions into neuronal stem cells and neurons that are copies of those in the patients» brains.

Scientists want to be able to clone early human embryos, using cells from patients with various diseases, so they can study the diseases in the lab and develop new treatments for them.

Researchers in Keele University's Research Institute for Science and Technology in Medicine and at the Haywood Rheumatology Centre, in Staffordshire, UK, and the University Hospitals of North Midlands NHS Trust, have for the first time identified disease - associated changes to the DNA epigenome in joint fluid cells from patients with rheumatoid arthritis.

A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer.

When Fishel and Kolodner heard of the accumulation of mutations in cancer cells from patients with familial colon cancer, they suspected that the gene responsible would be similar to the bacterial and yeast genes they had studied.

The disease model, described in a new study by a UC San Francisco - led team, involves taking skin cells from patients with the bone disease, reprogramming them in a lab dish to their embryonic state, and deriving stem cells from them.

Zheng, together with Leah Boyer, then a researcher in Gage's lab and now director of Salk's Stem Cell Core, generated diseased neurons by taking skin cells from patients with Leigh syndrome, reprogramming them into stem cells in culture and then coaxing them to develop into brain cells in a dish.

In a process called cellular reprogramming, researchers at Icahn School of Medicine at Mount Sinai have taken mature blood cells from patients with myelodysplastic syndrome (MDS) and reprogrammed them back into iPSCs to study the genetic origins of this rare blood cancer.

In this study, researchers took cells from patients with blood cancer MDS and turned them into stem cells to study the deletions of human chromosome 7 often associated with this disease.

In new research, scientists reprogrammed skin cells from patients with rare blood disorders into iPSCs, highlighting the great promise of these cells in advancing understanding of those challenging diseases — and eventually in treating them.

The new technique can also be used to grow muscle cells from iPS cells from patients with neuromuscular diseases like ALS, spinal muscular atrophy and muscular dystrophy.

They found that a certain protein, known as S100B, is markedly increased in astroglial cells from patients with Down syndrome compared with those from healthy controls.

The results of the empirical study show a clear distinction between the damage to the white blood cells from patients with cancer, with pre-cancerous conditions and from healthy patients.

In contrast, PD - L1 blockade increased the capacity of Treg cells to multiply (and hence their overall numbers), but only in cells from patients with viremia, i.e. those that had detectable virus in their blood.

Scientists could build chips containing cells from patients with specific genetic mutations, which could predict drug responses in specific populations, as well as personalized chips that predict an individual's drug response.

To develop their «disease in a dish» model, the team took skin cells from patients with Allan - Herndon - Dudley syndrome and reprogrammed them into induced pluripotent stem cells, which then can be developed into any type of tissue in the body.

The Muotri lab uses induced pluripotent stem cells from patients with autism and schizophrenia to look for biomarkers of these conditions.

Beginning in the 1970s, physicians learned how to harvest skin stem cells from a patient with extensive burn wounds, grow them in the laboratory, then apply the lab - grown tissue to close and protect a patient's wounds.

For example, by taking neural stem cells from a patient with schizophrenia, researchers might turn back the clock and track the onset of the condition in an organoid.

For instance, researchers at the Salk Institute in California have taken skin cells from a patient with the genetic disease Fanconi's anemia, often associated with leukemia.

In lab dishes, Liu's team corrected a mutation in human cells from a patient with an iron - storage blood disorder called hereditary hemochromatosis.

«Imagine if we could isolate fat cells from a patient with some type of congenital cardiac disease,» said Wu.

First, they took adult skin cells from a patient with an HBB mutation that causes sickle cell disease.

It is now almost routine to grow skin cells from a patient with, say, a neurological disease; turn them into pluripotent cells in a Petri dish; convert the cells into nerve cells to study the disease process; and contemplate using the cells to repair the same patient's damaged brain.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

«Scientists say they have replaced a 65 - year - old patient's upper jaw with a bone transplant cultivated from stem cells isolated from his own fatty tissue and grown inside his abdomen.»

In November the Lancet published the results of an international research project whereby a Colombian lady received a new trachea (windpipe) which had been grown from a donor trachea (as it were, a «scaffold») repopulated with stem cells, for the very first time, from the patient's own body.